American Oriental Bioengineering Reports Third Quarter 2008 Financial Results
More News related to AOB
- Roth Capital Starts American Oriental Bioengineering (AOB) at Buy
- American Oriental (AOB) Reports Q3 EPS In-Line
- American Oriental Bioengineering Reports Third Quarter 2008 Financial Results
- Lazard Downgrades American Oriental (AOB) to Hold
- Matrix USA Rating Changes 9/2
More News related to Press Releases
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
NEW YORK, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced financial results for the quarter ended September 30, 2008.
Financial Results
Revenue in the third quarter of 2008 increased 62% year over year to $70.6 million from $43.5 million, reflecting a continued increase in demand for the Company's OTC and prescription pharmaceutical products. Revenue from pharmaceutical products increased 75% to $62.1 million from $35.5 million in the third quarter of 2007. Revenue from OTC pharmaceutical products increased 91% to $37.8 million from $19.8 million in the prior year's third quarter, reflecting continued recognition of the Company's new products supported by effective marketing campaigns. Sales generated by CCXA and Boke, which were not subsidiaries in the third quarter of 2007, were major contributors to the increase in OTC sales and generated a combined $17.1 million of revenue during the third quarter of 2008. Strong sales of the Jinji series and Jinji Yimucao products also contributed to the increase in OTC revenue during the third quarter of 2008. Prescription pharmaceutical products generated $24.3 million in revenue during the third quarter of 2008, a 55% year over year increase. Prescription pharmaceutical sales increasingly reflect contributions from the Company's diversifying product portfolio, including recently launched CCXA prescription products, as well as from existing products. Expanding rural market coverage also drove prescription pharmaceutical revenue performance during the third quarter of 2008. Nutraceutical product revenue increased approximately 6% to $8.5 million in the third quarter of 2008 from $8.0 million in the prior year's period, and decreased as a percentage of total revenue to approximately 12% versus 18% in the comparable period. The increase in Nutraceutical revenue was mainly attributed to the increase in sales of peptide tablets and peptide powder. The Company continues to focus on selling and marketing higher growth pharmaceutical products.
Gross profit in the third quarter of 2008 increased 54% to $47.2 million from $30.7 million in the third quarter of 2007. Gross margin was approximately 66.9%, compared to 70.5% in the prior year's period, reflecting the integration of CCXA and a shift in product mix.
For the third quarter of 2008, operating expenses increased 52% to $25.3 million from $16.7 million in the comparable period of 2007. The increase in operating expenses was primarily due to increases in sales and marketing expenses, as well as additional depreciation and amortization costs due to the Boke and CCXA acquisitions. Income from operations in the third quarter of 2008 increased 56% to $21.8 million from $14.0 million in the third quarter of 2007, while operating margin was 31%, compared to 32% in the third quarter of the prior year.
Net income for the third quarter of 2008 increased 38% to $16.5 million, or $0.21 per diluted share, compared to $11.9 million, or $0.16 per diluted share, in the prior year's period. Diluted share count in the third quarter of 2008 was 85.4 million, compared to 75.3 million in the third quarter of 2007.
Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "We are very pleased with our financial performance in the third quarter of 2008, which demonstrates continued growth across all of our product categories. We are also extremely well-capitalized versus competitors, with over $220 million of cash and operating cash flow up 80% year over year. Lastly, our third quarter results support our confidence in our brand strength, expansion into rural markets, and unique positioning as a leading consolidator in China's healthcare space."
Mr. Liu concluded, "Today we are increasing our full year 2008 revenue expectation to at least $250 million, up from prior guidance of $245 million. We are reiterating our full year 2008 net income expectation of $62 million, which excludes convertible note interest expense for the second half of 2008, and also excludes any contributions from Nuo Hua and GHK acquisitions. These recently closed acquisitions should create several exciting opportunities for our Company including enhanced distribution reach in strategic areas like hospital pharmacies, new product development and expertise bringing new products to market in the future."
Conference Call
The Company will hold a conference call at 8:00 am ET on November 10, 2008 to discuss its fiscal third quarter 2008 results. Listeners may access the call by dialing 1-866-578-5801 or 1-617-213-8058 for international callers, access code: 73013671. A webcast will also be available through AOBO's website at http://www.bioaobo.com . A replay of the call will be available through November 17, 2008. Listeners may access the replay by dialing 1-888- 286-8010 or 1-617-801-6888 for international callers, access code: 59642931.
About American Oriental Bioengineering Inc.
American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China.
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended September 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
ASSETS
SEPTEMBER 30, DECEMBER 31,
2008 2007
UNAUDITED
CURRENT ASSETS
Cash and cash equivalents $219,727,043 $166,410,075
Accounts receivable, net of reserve
of $224,333 and $302,270 at
September 30, 2008 and December 31,
2007, respectively 24,556,175 16,494,619
Inventories, net 17,251,005 12,264,536
Advances to suppliers 1,467,388 4,309,352
Notes receivable 589,725 2,259,616
Refundable deposit 6,386,418 --
Deferred tax assets 529,813 --
Other current assets 615,765 5,134,118
Total Current Assets 271,123,332 206,872,316
LONG-TERM ASSETS
Plant and equipment, net 70,082,061 48,496,760
Land use rights, net 63,883,307 46,310,240
Deposit for long-term assets 23,565,407 --
Construction-in-progress 446,203 755,614
Other intangible assets, net 24,968,293 26,972,166
Goodwill 22,566,768 22,566,768
Investments in and advances to equity
investments 21,479,515 242,551
Deferred tax assets 1,344,484 1,498,481
Unamortized financing cost 4,448,056 --
Total Long-Term Assets 232,784,094 146,842,580
TOTAL ASSETS $503,907,426 $353,714,896
AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
LIABILITIES AND SHAREHOLDERS' EQUITY
SEPTEMBER 30, DECEMBER 31,
2008 2007
UNAUDITED
CURRENT LIABILITIES
Accounts payable $4,788,336 $3,436,352
Other payables and accrued expenses 12,679,625 7,786,157
Taxes payable 4,485,151 2,843,719
Short-term bank loans 6,710,332 6,289,222
Current portion of long-term bank
loans 2,966,016 2,374,565
Other liabilities 2,263,080 3,621,030
Deferred tax liabilities 680,544 109,733
Total Current
Liabilities 34,573,084 26,460,778
LONG-TERM LIABILITIES
Long-term bank loans, net of current
portion 818,058 1,263,483
Long-term notes payable 297,390 286,365
Deferred tax liabilities 16,390,430 12,621,180
Convertible Note 115,000,000 --
Total Long-Term
Liabilities 132,505,878 14,171,028
TOTAL LIABILITIES 167,078,962 40,631,806
COMMITMENTS
SHAREHOLDERS' EQUITY
Preferred stock, $0.001 par value;
2,000,000 shares authorized;
1,000,000 shares issued and
outstanding at September 30, 2008
and December 31, 2007, respectively 1,000 1,000
Common stock, $0.001 par value;
150,000,000 shares authorized;
78,249,264 and 77,991,935 shares
issued and outstanding at September
30, 2008 and December 31, 2007,
respectively 78,249 77,992
Common stock to be issued 279,332 1,611,333
Prepaid forward repurchase contract (29,998,616) --
Additional paid-in capital 195,500,513 193,007,987
Retained earnings (the restricted
portion of retained earnings is
$15,910,685 at September 30, 2008
and December 31, 2007, respectively) 141,882,532 102,117,792
Accumulated other comprehensive
income 29,085,454 16,266,986
Total Shareholders'
Equity 336,828,464 313,083,090
TOTAL LIABILITIES AND
SHAREHOLDERS' EQUITY $503,907,426 $353,714,896
AMERICAN ORIENTAL BIOENGINEERING, INC. AND
SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF
INCOME AND COMPREHENSIVE
INCOME (UNAUDITED)
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
2008 2007 2008 2007
REVENUES $70,593,949 $43,514,049 $168,372,552 $103,062,573
COST OF GOODS
SOLD 23,402,407 12,833,252 54,808,490 31,048,916
GROSS PROFIT 47,191,542 30,680,797 113,564,062 72,013,657
Selling and
marketing 9,938,877 5,644,776 22,656,477 12,210,509
Advertising 9,913,728 6,934,160 21,760,300 16,150,754
General and
administrative 4,467,638 3,742,364 13,633,595 9,234,426
Depreciation
and
amortization 1,024,436 377,856 3,012,107 1,054,128
Total
operating
expenses 25,344,679 16,699,156 61,062,479 38,649,817
INCOME FROM
OPERATIONS 21,846,863 13,981,641 52,501,583 33,363,840
EQUITY IN
EARNINGS
(LOSS) FROM
UNCONSOLIDATED
ENTITIES 49,417 3,953 (591,650) 14,848
INTEREST INCOME
(EXPENSE), NET (1,143,013) 360,365 (1,156,782) 375,604
OTHER INCOME
(EXPENSE), NET 91,986 (16,144) (264,515) 118,436
INCOME BEFORE
INCOME TAXES 20,845,253 14,329,815 50,488,636 33,872,728
INCOME TAXES 4,362,334 2,386,189 10,723,896 5,846,543
NET INCOME 16,482,919 11,943,626 39,764,740 28,026,185
OTHER
COMPREHENSIVE
INCOME
Foreign
currency
translation
gain, net of
tax 729,272 1,992,992 12,818,468 4,884,314
TOTAL OTHER
COMPREHENSIVE
INCOME, NET OF
TAX 729,272 1,992,992 12,818,468 4,884,314
COMPREHENSIVE
INCOME $17,212,191 $13,936,618 52,583,208 $32,910,499
NET INCOME PER
SHARE
BASIC $0.22 $0.16 0.52 $0.41
DILUTED $0.21 $0.16 0.50 $0.40
WEIGHTED
AVERAGE NUMBER
OF SHARES
OUTSTANDING
BASIC 75,101,869 74,379,650 77,164,602 68,012,018
DILUTED 85,417,621 75,331,015 80,553,647 69,234,193
SOURCE American Oriental Bioengineering Inc.
Related Categories
Press ReleasesStocks Mentioned
-0.26Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
